![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
US Physical Therapy Inc | NYSE:USPH | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 94.48 | 0 | 01:00:00 |
Management Raises Earnings Guidance
Company Increases Quarterly Dividend
U.S. Physical Therapy, Inc. ("USPH" or the “Company”) (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today reported results for the second quarter and six months ended June 30, 2021 (“2021 Second Quarter” and “2021 Six Months”, respectively).
HIGHLIGHTS
SUMMARY OF 2021 SECOND QUARTER AND SIX MONTHS RESULTS
For the 2021 Second Quarter, USPH’s Operating Results was $12.4 million, or $0.96 per diluted share, an increase of 30.5% as compared to $9.5 million (inclusive of Relief Funds), or $0.74 per diluted share, for the 2020 Second Quarter. Operating Results per diluted share for the 2021 Second Quarter was also higher than the $0.81 per diluted share for the pre-pandemic 2019 Second Quarter by $0.15, or 18.5%. For the six months ended June 30, 2021 (“2021 Six Months”), USPH’s Operating Results was $20.6 million, or $1.60 per diluted share, an increase of 54.0%, as compared to $13.4 million, or $1.04 per diluted share, for the six months ended June 30, 2020 (“2020 Six Months”). Operating Results per diluted share for the 2021 Six Months was also higher than the $1.47 per diluted share for the six months ended June 30, 2019 (“2019 Six Months) by $0.13, or 8.8%. Operating Results, a non-Generally Accepted Accounting Principles (“GAAP”) measure, equals net income attributable to USPH diluted shareholders per the consolidated statements of income less gain on sale of partnership interests and clinics plus charges incurred for clinic closure costs and expenses related to CFO transition, all net of taxes. Also, Operating Results earnings per diluted share excludes the impact of the revaluation of redeemable non-controlling interest and the associated tax impact. See tables on pages 15 and 16.
For the 2021 Second Quarter, USPH’s net income attributable to its diluted shareholders was $12.4 million, as compared to $10.2 million for the 2020 Second Quarter and $14.6 million for the 2019 Second Quarter, which includes a $5.8 million gain on the sale of the Company’s interest in a physical therapy partnership on June 30, 2019. For the 2021 Six Months, USPH’s net income attributable to its diluted shareholders was $20.6 million, as compared to $11.2 million for the 2020 Six Months and $23.0 million for the 2019 Six Months. Inclusive of the charge or credit for revaluation of non-controlling interest, net of taxes, used to compute diluted earnings per diluted share in accordance with GAAP, the amount is $10.5 million, or $0.82 per diluted share, for the 2021 Second Quarter as compared to $12.7 million, or $0.99 per diluted share, for the 2020 Second Quarter, and $0.85 per diluted share for the 2019 Second Quarter. Inclusive of the charge or credit for revaluation of redeemable non-controlling interest, net of taxes, used to compute diluted earnings per diluted share in accordance with GAAP, the amount is $13.3 million, or $1.03 per diluted share, for the 2021 Six Months as compared to $15.3 million, or $1.19 per diluted share, for the 2020 Six Months, and $15.8 million or $1.24 per diluted share for the 2019 Six Months. In accordance with current accounting guidance, the revaluation of redeemable non-controlling interest, net of taxes, is not included in net income but charged directly to retained earnings; however, the charge or credit for this change is included in the earnings per basic and diluted share calculation. See the schedules on pages 15 and 16 for the computation of earnings per diluted share. In 2020, the valuation of redeemable non-controlling interests decreased due to the results associated with the pandemic, therefore resulting in a credit to retained earnings. In 2021 and 2019, the valuations increased therefore there was a charge to retained earnings.
As previously disclosed in a series of filings with the SEC and further described in detail in our Quarterly Reports on Form 10-Q for the first three quarters of 2020 and our Annual Report on Form 10-K, the Company’s results were negatively impacted by the effects of the COVID-19 pandemic in the 2020. For 2021 periods as compared to 2020 periods, the increase in revenues and expenses are largely due to the Company returning to pre-pandemic volumes.
Second Quarter 2021 Compared to Second Quarter 2020
Three Months Ended
June 30, 2021
June 30, 2020
Revenue related to Mature Clinics
$
105,223
$
69,567
Revenue related to 2021 Clinic Additions
2,458
-
Revenue related to 2020 Clinic Additions
5,531
1,952
Revenue from clinics sold or closed in 2021
24
102
Revenue from clinics sold or closed in 2020
2
658
Net patient revenues from physical therapy operations
113,238
72,279
Other revenue
918
328
Revenue from physical therapy operations
114,156
72,607
Management contract revenue
2,739
1,592
Industrial injury prevention services
10,033
9,658
Total Revenue
$
126,928
$
83,857
Three Months Ended
June 30, 2021
June 30, 2020
Operating costs related to Mature Clinics
$
75,988
$
53,767
Operating costs related to 2021 Clinic Additions
2,019
-
Operating costs related to 2020 Clinic Additions
4,934
1,513
Operating costs related to clinics sold or closed in 2021
(2
)
132
Operating costs related to clinics sold or closed in 2020
14
1,425
Physical therapy operations
82,953
56,837
Physical therapy management contracts
2,202
1,163
Industrial injury prevention services
7,491
6,479
$
92,646
$
64,479
Three Months Ended
June 30, 2021
June 30, 2020
Gross profit, excluding closure costs:
Physical therapy operations
$
31,203
$
15,770
Management contracts
536
429
Industrial injury prevention services
2,543
3,179
Gross profit, excluding closure costs
$
34,282
$
19,378
Physical therapy operations - closure costs
(22
)
94
Gross profit
$
34,304
$
19,284
Three Months Ended
June 30, 2021
June 30, 2020
Income before taxes
$
22,039
$
18,645
Less: net income attributable to non-controlling interests:
Redeemable non-controlling interests - temporary equity
(3,611
)
(2,996
)
Non-controlling interests - permanent equity
(1,425
)
(1,535
)
$
(5,036
)
$
(4,531
)
Income before taxes less net income attributable to non-controlling interests
$
17,003
$
14,114
Provision for income taxes
$
4,567
$
3,882
Percentage
26.9
%
27.5
%
2021 Six Months Compared to 2020 Six Months
For the Six Months Ended
June 30, 2021
June 30, 2020
Revenue related to Mature Clinics
$
199,068
$
165,277
Revenue related to 2021 Clinic Additions
2,549
-
Revenue related to 2020 Clinic Additions
10,732
2,930
Revenue from clinics sold or closed in 2021
141
333
Revenue from clinics sold or closed in 2020
2
3,865
Net patient revenues from physical therapy operations
212,492
172,405
Other revenue
1,464
895
Revenue from physical therapy operations
213,956
173,300
Management contract revenue
5,297
3,740
Industrial injury prevention services
20,043
19,534
Total Revenue
$
239,296
$
196,574
For the Six Months Ended
June 30, 2021
June 30, 2020
Operating costs related to Mature Clinics
$
147,975
$
132,591
Operating costs related to 2021 Clinic Additions
2,161
-
Operating costs related to 2020 Clinic Additions
9,569
2,272
Operating costs related to clinics sold or closed in 2021
154
395
Operating costs related to clinics sold or closed in 2020
(4
)
4,829
Physical therapy operations
159,855
140,087
Physical therapy management contracts
4,448
2,975
Industrial injury prevention services
14,778
14,691
$
179,081
$
157,753
For the Six Months Ended
June 30, 2021
June 30, 2020
Gross profit, excluding closure costs:
Physical therapy operations
$
54,101
$
33,213
Management contracts
849
765
Industrial injury prevention services
5,265
4,843
Gross profit, excluding closure costs
$
60,215
$
38,821
Physical therapy operations - closure costs
15
3,846
Gross profit
$
60,200
$
34,975
For the Six Months Ended
June 30, 2021
June 30, 2020
Income before taxes
$
36,869
$
22,275
Less: net income attributable to non-controlling interests:
Non-controlling interests - permanent equity
(6,064
)
(4,792
)
Redeemable non-controlling interests - temporary equity
(2,685
)
(2,061
)
$
(8,749
)
$
(6,853
)
Income before taxes less net income attributable to non-controlling interests
$
28,120
$
15,422
Provision for income taxes
$
7,511
$
4,174
Percentage
26.7
%
27.1
%
Medicare Accelerated and Advance Payment Program (“MAAPP Funds”)
In response to the COVID-19 pandemic, the federal government approved the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). The CARES Act allowed for qualified healthcare providers to receive advanced payments under the MAAPP Funds during the COVID-19 pandemic. Under this program, healthcare providers could choose to receive advanced payments for future Medicare services provided. The Company applied for and received approval from Centers for Medicare & Medicaid Services (“CMS”) in April 2020. The Company recorded the $14.1 million in advance payments received as a liability. During the first quarter of 2021, the Company repaid the MAAPP Funds of $14.1 million rather than applying them to future services performed.
Relief Funds
On March 27, 2020, the CARES Act was enacted. The CARES Act provided additional waivers, reimbursement, grants and other funds to assist health care providers during the COVID-19 pandemic, including $100.0 billion in appropriations for the Public Health and Social Services Emergency Fund, also referred to as the Provider Relief Fund, to be used for preventing, preparing, and responding to the coronavirus, and for reimbursing eligible health care providers for lost revenues and health care related expenses that are attributable to COVID-19.
Through December 31, 2020, the Company’s consolidated subsidiaries received approximately $13.5 million of payments under the CARES Act (“Relief Funds”). Under the Company’s accounting policy, these payments were recorded as Other income – Relief Funds. These funds are not required to be repaid upon attestation and compliance with certain terms and conditions, which could change materially based on evolving grant compliance provisions and guidance provided by the U.S. Department of Health and Human Services. Currently, the Company can attest and comply with the terms and conditions. The Company will continue to monitor the evolving guidelines and may record adjustments as additional information is released. There were no Relief Funds received in the 2021 Six Months.
Other Financial Measures
For the 2021 Second Quarter, the Company's Adjusted EBITDA was $21.8 million, an increase of $2.8 million, or 14.5%, compared to $19.0 million for the 2020 Second Quarter, inclusive of Relief Funds and an increase of $2.7 million, or 14.1%, compared to $19.1 million for the 2019 Second Quarter. For the 2021 Six Months, the Company's Adjusted EBITDA was $37.4 million compared to $27.0 million for the 2020 Six Months inclusive of Relief Funds, and $34.7 million for the 2019 Six Months. See definition, explanation and calculation of Adjusted EBITDA in the schedule on pages 15 and 16.
Acquisition in Second Quarter 2021
As previously reported, the Company acquired a 65% interest in an eight-clinic physical therapy practice at the end of the 2021 Second Quarter with the practice founder retaining 35%. The purchase price was approximately $10.3 million, of which $9.0 million was paid in cash, $1.0 million is payable based on certain criteria and $0.3 million is in a note payable. The business generates $7.3 million in annual revenue and has approximately 65,000 annual patient visits. The Company’s strategy is to continue acquiring multi-clinic outpatient physical therapy practices, to develop outpatient physical therapy clinics as satellites in existing partnerships and to continue acquiring companies that provide industrial injury prevention services.
Quarterly Dividend
In response to the Company’s strong performance thus far in 2021 and confidence in its future performance, the Company’s Board of Directors increased the Company’s quarterly dividend on August 3, 2021, from $0.35 per share to $0.38 per share, an increase of 8.6%. The Board of Directors subsequently declared a quarterly dividend of $0.38 per share which will be paid on September 17, 2021 to shareholders of record as of August 20, 2021.
Management Revises 2021 Earnings Guidance
Management currently expects the Company’s Operating Results for 2021 to be in the range of $39.4 million to $40.6 million, or $3.05 to $3.15 per diluted share. The increase in the guidance range is attributable to the Company’s strong performance for the 2021 Second Quarter, the impact of the acquisition closed in the 2021 Second Quarter, and confidence in the sustainability of the Company’s performance through the remainder of 2021.
This earnings range is based on an estimated annual effective tax rate of approximately 27.0%. Please note that the earnings guidance represents projected Operating Results from existing operations and excludes future acquisitions. The 2021 earnings guidance range excludes expenses associated with the previously-announced retirement and replacement of one of the Company’s co-Chief Operating Officers. The annual guidance figures will not be updated unless there is a material development that causes management to believe that Operating Results will be significantly outside the given range.
Management’s Comments
Chris Reading, Chief Executive Officer, said, “Throughout this last year and a half our partners, directors and clinical staff have done a truly exemplary job providing excellent care in a very challenging environment. As evidenced by our record visits per clinic per day numbers this quarter, our patients and referral sources continue to seek us out for care. I remain very grateful for our entire team’s efforts through this COVID-19 pandemic. It hasn’t been easy, but throughout our organization across our many partnerships and in every support department, our people have truly risen to the challenge.”
Carey Hendrickson, Chief Financial Officer, said, “Our balance sheet remains in a very solid position and our record-high volumes are resulting in outstanding cash generation. We are pleased with the excellent results generated by our team in the first half of 2021, and we are confident in the Company’s future performance as signaled by the raising of our full year 2021 guidance range for the second time this year and the interim increase in our quarterly dividend rate.”
Second Quarter 2021 Conference Call
U.S. Physical Therapy's management will host a conference call at 10:30 a.m. Eastern Time, 9:30 a.m. Central Time, on August 5, 2021 to discuss results for the Company's 2021 Second Quarter. Interested parties may participate in the call by dialing 1-888-335-5539 or 973-582-2857 and entering reservation number 7486602 approximately 10 minutes before the call is scheduled to begin. To listen to the live call via web-cast, go to the Company's website at www.usph.com at least 15 minutes early to register, download and install any necessary audio software. The conference call will be archived and can be accessed until November 5, 2021 at U.S. Physical Therapy’s website.
Forward-Looking Statements
This press release contains statements that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934, as amended. These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we expect. Included among such statements may be those relating to new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:
See Risk Factors in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020.
Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. Please see the other sections of this report and our other periodic reports filed with the Securities and Exchange Commission (the “SEC”) for more information on these factors. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement, regardless of the reason the statement may no longer be accurate.
About U.S. Physical Therapy, Inc.
Founded in 1990, U.S. Physical Therapy, Inc. operates 575 outpatient physical therapy clinics in 39 states. The Company's clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. In addition to owning and operating clinics, the Company manages 39 physical therapy facilities for unaffiliated third parties, including hospitals and physician groups. The Company also has an industrial injury prevention business which provides onsite services for clients’ employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments. More information about U.S. Physical Therapy, Inc. is available at www.usph.com. The information included on that website is not incorporated into this press release.
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(unaudited)
Three Months Ended
For the Six Months Ended
June 30, 2021
June 30, 2020
June 30, 2021
June 30, 2020
Net patient revenues
$
113,238
$
72,279
$
212,492
$
172,405
Other revenues
13,690
11,578
26,804
24,169
Net revenues
126,928
83,857
239,296
196,574
Operating costs:
Salaries and related costs
68,866
43,429
132,681
112,433
Rent, supplies, contract labor and other
22,416
20,311
43,836
43,220
Provision for credit losses
1,364
739
2,564
2,100
Closure costs - lease and other
(22
)
94
15
1,987
Closure costs - derecognition of goodwill
-
-
-
1,859
Total operating costs
92,624
64,573
179,096
161,599
Gross profit
34,304
19,284
60,200
34,975
Corporate office costs
12,074
9,022
22,948
20,699
Operating income
22,230
10,262
37,252
14,276
Other income and expense
Relief Funds
-
7,959
-
7,959
Gain on sale of partnership interest and clinics
-
1,073
-
1,073
Interest and other income, net
46
4
100
47
Interest expense - debt and other
(237
)
(653
)
(483
)
(1,080
)
Total other income and expense
(191
)
8,383
(383
)
7,999
Income before taxes
22,039
18,645
36,869
22,275
Provision for income taxes
4,567
3,882
7,511
4,174
Net income
17,472
14,763
29,358
18,101
Less: net income attributable to non-controlling interests:
Redeemable non-controlling interests - temporary equity
(3,611
)
(2,996
)
(6,064
)
(4,792
)
Non-controlling interests - permanent equity
(1,425
)
(1,535
)
(2,685
)
(2,061
)
(5,036
)
(4,531
)
(8,749
)
(6,853
)
Net income attributable to USPH shareholders
$
12,436
$
10,232
$
20,609
$
11,248
Basic and diluted earnings per share attributable to USPH shareholders
$
0.82
$
0.99
$
1.03
$
1.19
Shares used in computation - basic and diluted
12,902
12,843
12,886
12,820
Dividends declared per common share
$
0.35
$
-
$
0.70
$
0.32
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEET
(IN THOUSANDS, EXCEPT PER SHARE DATA)
June 30, 2021
December 31, 2020
ASSETS
(unaudited)
Current assets:
Cash and cash equivalents
$
20,419
$
32,918
Patient accounts receivable, less allowance for credit losses of $2,435 and $2,008, respectively
45,144
41,906
Accounts receivable - other
9,025
9,039
Other current assets
5,111
3,773
Total current assets
79,699
87,636
Fixed assets:
Furniture and equipment
57,538
55,426
Leasehold improvements
35,986
35,320
Fixed assets, gross
93,524
90,746
Less accumulated depreciation and amortization
71,964
69,081
Fixed assets, net
21,560
21,665
Operating lease right-of-use assets
87,090
81,595
Goodwill
373,887
345,646
Other identifiable intangible assets, net
59,216
56,280
Other assets
1,506
1,539
Total assets
$
622,958
$
594,361
LIABILITIES, REDEEMABLE NON-CONTROLLING INTERESTS, USPH SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS
Current liabilities:
Accounts payable - trade
$
1,782
$
1,335
Accrued expenses
44,720
59,746
Current portion of operating lease liabilities
27,860
27,512
Current portion of notes payable
1,017
4,899
Total current liabilities
75,379
93,492
Notes payable, net of current portion
821
596
Revolving line of credit
38,000
16,000
Deferred taxes
8,281
7,779
Operating lease liabilities, net of current portion
66,887
61,985
Other long-term liabilities
5,442
4,539
Total liabilities
194,810
184,391
Redeemable non-controlling interests - temporary equity
143,337
132,340
Commitments and Contingencies
U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity:
Preferred stock, $.01 par value, 500,000 shares authorized, no shares issued and outstanding
-
-
Common stock, $.01 par value, 20,000,000 shares authorized,
15,121,669 and 15,066,282 shares issued, respectively
151
151
Additional paid-in capital
99,039
95,622
Retained earnings
216,286
212,015
Treasury stock at cost, 2,214,737 shares
(31,628
)
(31,628
)
Total USPH shareholders’ equity
283,848
276,160
Non-controlling interests - permanent equity
963
1,470
Total USPH shareholders' equity and non-controlling interests - permanent equity
284,811
277,630
Total liabilities, redeemable non-controlling interests,
USPH shareholders' equity and non-controlling interests - permanent equity
$
622,958
$
594,361
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(unaudited)
Six Months Ended
June 30, 2021
June 30, 2020
OPERATING ACTIVITIES
Net income including non-controlling interests
$
29,358
$
18,101
Adjustments to reconcile net income including non-controlling interests to net cash provided by operating activities:
Depreciation and amortization
5,484
5,333
Provision for credit losses
2,564
2,100
Equity-based awards compensation expense
3,405
3,389
Deferred income taxes
3,160
(1,737
)
Loss on sale of fixed assets
106
429
Gain on sale of partnership interest
-
(1,073
)
Derecognition (write-off) of goodwill - closed clinics
-
1,859
Changes in operating assets and liabilities:
(Increase) decrease in patient accounts receivable
(5,325
)
8,880
Decrease in accounts receivable - other
129
283
(Increase) decrease in other assets
(255
)
5,969
(Decrease) increase in accounts payable and accrued expenses
(3,672
)
4,478
Increase in other long-term liabilities
602
345
Net cash provided by operating activities
35,556
48,356
INVESTING ACTIVITIES
Purchase of fixed assets
(3,301
)
(4,628
)
Purchase of majority interest in businesses, net of cash acquired
(20,402
)
(11,633
)
Purchase of redeemable non-controlling interest, temporary equity
(9,536
)
(2,388
)
Purchase of non-controlling interest, permanent equity
-
(144
)
Proceeds on sale of redeemable non-controlling interest, temporary equity
32
19
Proceeds on sales of partnership interest, clinics and fixed assets
(168
)
695
Net cash used in investing activities
(33,375
)
(18,079
)
FINANCING ACTIVITIES
Distributions to non-controlling interests, permanent and temporary equity
(9,398
)
(5,707
)
Cash dividends paid to shareholders
(9,028
)
(4,110
)
Proceeds from revolving line of credit
128,000
99,000
Payments on revolving line of credit
(106,000
)
(112,000
)
Principal payments on notes payable
(4,207
)
(314
)
(Payment) receipt of Medicare Accelerated and Advance Funds
(14,054
)
12,861
Other
7
-
Net cash used in financing activities
(14,680
)
(10,270
)
Net (decrease) increase in cash and cash equivalents
(12,499
)
20,007
Cash and cash equivalents - beginning of period
32,918
23,548
Cash and cash equivalents - end of period
$
20,419
$
43,555
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid during the period for:
Income taxes
$
6,967
$
57
Interest
$
741
$
944
Non-cash investing and financing transactions during the period:
Purchase of businesses - seller financing portion
$
550
$
300
Purchase of businesses - payable
$
1,000
$
-
Purchase of redeemable non-controlling interest - notes payable
$
-
$
137
Notes payable due to purchase of non-controlling interest, permanent equity
$
-
$
699
Note receivables related to sale of partnership interest
$
287
$
386
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES OPERATING RESULTS AND ADJUSTED EBITDA (IN THOUSANDS, EXCEPT PER SHARE DATA) (unaudited)
The following tables provide detail of the diluted earnings per share computation and reconcile net income attributable to USPH shareholders calculated in accordance with GAAP to Operating Results and Adjusted EBITDA. Management believes providing Operating Results and Adjusted EBITDA to investors is useful information for comparing the Company's period-to-period results.
Operating Results, a non-Generally Accepted Accounting Principles (“GAAP”) measure, equals net income attributable to USPH diluted shareholders per the consolidated statements of income less gain on sale of partnership interests and clinics plus charges incurred for clinic closure costs and expenses related to CFO transition, all net of taxes. The earnings per share from Operating Results also excludes the impact of the revaluation of redeemable non-controlling interest. In accordance with current accounting guidance, the revaluation of redeemable non-controlling interest, net of tax, is included in the earnings per basic and diluted share calculation, although it is not included in net income but charged directly to retained earnings.
Adjusted EBITDA is defined as net income attributable to USPH shareholders before interest income, interest expense, taxes, depreciation, amortization, equity-based awards compensation expense and derecognition of goodwill related to clinic closures. Management believes reporting Adjusted EBITDA is useful information for investors in comparing the Company’s period-to-period results as well as comparing with similar businesses which report adjusted EBITDA as defined by their company.
Management uses Operating Results and Adjusted EBITDA, which eliminates certain items described above that can be subject to volatility and unusual costs, as one the principal measures to evaluate and monitor financial performance period over period. Management believes that Operating Results and Adjusted EBITDA is useful information for investors to use in comparing the Company's period-to-period results as well as for comparing with other similar businesses since most do not have redeemable instruments and therefore have different equity structures.
Operating Results and Adjusted EBITDA are not measures of financial performance under GAAP. Adjusted EBITDA and Operating Results should not be considered in isolation or as an alternative to, or substitute for, net income attributable to USPH shareholders presented in the consolidated financial statements.
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
OPERATING RESULTS AND ADJUSTED EBITDA
2021 PERIODS COMPARED TO 2020 PERIODS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(unaudited)
Three Months Ended June 30,
Six Months Ended June 30,
2021
2020
2021
2020
Computation of earnings per share - USPH shareholders:
Net income attributable to USPH shareholders
$
12,436
$
10,232
$
20,609
$
11,248
Credit (charges) to retained earnings:
Revaluation of redeemable non-controlling interest
(2,549
)
3,344
(9,819
)
5,473
Tax effect at statutory rate (federal and state) of 25.55% and 26.25%, respectively
651
(878
)
2,508
(1,437
)
$
10,538
$
12,698
$
13,298
$
15,284
Earnings per share (basic and diluted)
$
0.82
$
0.99
$
1.03
$
1.19
Adjustments:
Closure costs
(22
)
94
15
3,846
Expenses related to CFO transition
-
-
-
133
Gain on sale of partnership interest and clinics
-
(1,073
)
-
(1,073
)
Relief Funds
-
(7,958
)
-
(7,958
)
Allocation to non-controlling interest
-
1,900
-
1,900
Revaluation of redeemable non-controlling interest
2,549
(3,344
)
9,819
(5,473
)
Tax effect at statutory rate (federal and state) of 25.55% and 26.25%, respectively
(651
)
2,725
(2,508
)
2,264
Operating Results (without Relief Funds)
$
12,414
$
5,042
$
20,624
$
8,923
Relief Funds
$
-
7,958
$
-
7,958
Allocation to non-controlling interest
-
(1,900
)
-
(1,900
)
Tax effect at statutory rate (federal and state) of 26.25%
-
(1,590
)
-
(1,590
)
Operating Results (including Relief Funds)
$
12,414
$
9,510
$
20,624
$
13,391
Basic and diluted Operating Results (without Relief Funds) per share
$
0.96
$
0.39
$
1.60
$
0.70
Basic and diluted Operating Results (including Relief Funds) per share
$
0.96
$
0.74
$
1.60
$
1.04
Shares used in computation - basic and diluted
12,902
12,843
12,886
12,820
Three Months Ended June 30,
Six Months Ended June 30,
2021
2020
2021
2020
Net income attributable to USPH shareholders
$
12,436
$
10,232
$
20,609
$
11,248
Adjustments:
Depreciation and amortization
2,803
2,726
5,484
5,333
Closure costs - derecognition of goodwill
-
-
-
1,859
Relief Funds
-
(7,958
)
(7,958
)
Interest income
(46
)
(4
)
(100
)
(47
)
Interest expense - debt and other
236
653
483
1,080
Provision for income taxes
4,567
3,882
7,511
4,174
Equity-based awards compensation expense
1,754
1,503
3,405
3,389
Adjusted EBITDA (without Relief Funds)
$
21,750
$
11,034
$
37,392
$
19,078
Relief Funds
-
7,958
7,958
Adjusted EBITDA
$
21,750
$
18,992
$
37,392
$
27,036
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
OPERATING RESULTS AND ADJUSTED EBITDA
2021 PERIODS COMPARED TO 2019 PERIODS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(unaudited)
Three Months Ended June 30,
Six Months Ended June 30,
2021
2019
2021
2019
Computation of earnings per share - USPH shareholders:
Net income attributable to USPH shareholders
$
12,436
$
14,620
$
20,609
$
23,063
Credit (charges) to retained earnings:
Revaluation of redeemable non-controlling interest
(2,549
)
(5,169
)
(9,819
)
(9,830
)
Tax effect at statutory rate (federal and state) of 25.55% and 26.25%, respectively
651
1,356
2,508
2,580
$
10,538
$
10,807
$
13,298
$
15,813
Earnings per share (basic and diluted)
$
0.82
$
0.85
$
1.03
$
1.24
Adjustments:
Closure costs
(22
)
-
15
-
Expenses related to CFO transition
-
-
-
-
Gain on sale of partnership interest and clinics
-
(5,823
)
-
(5,823
)
Revaluation of redeemable non-controlling interest
2,549
5,169
9,819
9,830
Tax effect at statutory rate (federal and state) of 25.55% and 26.25%, respectively
(651
)
172
(2,508
)
(1,052
)
Operating Results
$
12,414
$
10,325
$
20,624
$
18,768
Basic and diluted Operating Results per share
$
0.96
$
0.81
$
1.60
$
1.47
Shares used in computation - basic and diluted
12,902
12,767
12,886
12,738
Three Months Ended June 30,
Six Months Ended June 30,
2021
2019
2021
2019
Net income attributable to USPH shareholders
$
12,436
$
14,620
$
20,609
$
23,063
Adjustments:
Depreciation and amortization
2,803
2,520
5,484
4,920
Gain on sale of partnership interest
-
(5,823
)
-
(5,823
)
Interest income
(46
)
(4
)
(100
)
(20
)
Interest expense - debt and other
236
607
483
965
Provision for income taxes
4,567
5,318
7,511
8,026
Equity-based awards compensation expense
1,754
1,830
3,405
3,558
Adjusted EBITDA
$
21,750
$
19,068
$
37,392
$
34,689
U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
RECAP OF PHYSICAL THERAPY OPERATIONS
CLINIC COUNT
Date
Number of Clinics
March 31, 2020
567
June 30, 2020
554
September 30, 2020
550
December 31, 2020
554
March 31, 2021
564
June 30, 2021
575
View source version on businesswire.com: https://www.businesswire.com/news/home/20210805005193/en/
U.S. Physical Therapy, Inc. Carey Hendrickson, Chief Financial Officer email: chendrickson@usph.com Chris Reading, Chief Executive Officer (713) 297-7000 Three Part Advisors Joe Noyons (817) 778-8424
1 Year US Physical Therapy Chart |
1 Month US Physical Therapy Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions